4-fluoro-3-hydroxy-N-(6-hydroxy-1,3-benzothiazol-2-yl)-N-methylbenzamide | 1361252-85-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-fluoro-3-hydroxy-N-(6-hydroxy-1,3-benzothiazol-2-yl)-N-methylbenzamide
• CAS: 1361252-85-8
• 化学式: C₁₅H₁₁FN₂O₃S
• 分子量: 318.328
• InChiKey: VNFKNZZMHWECIY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  102
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2-氨基-6-甲氧基苯并噻唑 在 吡啶 、 三溴化硼 、 sodium hydride 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 27.5h， 生成 4-fluoro-3-hydroxy-N-(6-hydroxy-1,3-benzothiazol-2-yl)-N-methylbenzamide
  参考文献：
  名称：

  Optimization of Hydroxybenzothiazoles as Novel Potent and Selective Inhibitors of 17β-HSD1

  摘要：

  17 beta-HSD1 is a novel target for the treatment of estrogen-dependent diseases, as it catalyzes intracellular estradiol formation. Starting from two recently described compounds, highly active and selective inhibitors were developed. Benzoyl 6 and benzamide 17 are the most selective compounds toward 17 beta-HSD2 described so far. They also showed a promising profile regarding activity in T47-D cells, selectivity toward ER alpha and ER beta inhibition of hepatic CYP enzymes, metabolic stability, and inhibition of marmoset 17 beta-HSD1 and 17 beta-HSD2.

  DOI：

  10.1021/jm201711b

文献信息

• [EN] SELECTIVE 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS<br/>[FR] INHIBITEURS SÉLECTIFS DE LA 17-BÊTA-HYDROXYSTÉROÏDE DÉSHYDROGÉNASE DE TYPE 1
  申请人：UNIV SAARLAND

  公开号：WO2012025638A1

  公开（公告）日：2012-03-01

  The invention relates to selective, non-steroidal 17beta-hydroxysteroid dehydrogenase type 1 (17β-HSD1) inhibitors their production and use, especially for the treatment and/or prophylaxis of hormone-related diseases.

  这项发明涉及选择性的、非类固醇17β-羟基类固醇脱氢酶1型（17β-HSD1）抑制剂的生产和使用，特别用于治疗和/或预防激素相关疾病。
• SELECTIVE 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS
  申请人：Universität des Saarlandes

  公开号：EP2609089A1

  公开（公告）日：2013-07-03
• Optimization of Hydroxybenzothiazoles as Novel Potent and Selective Inhibitors of 17β-HSD1
  作者：Alessandro Spadaro、Martin Frotscher、Rolf W. Hartmann

  DOI：10.1021/jm201711b

  日期：2012.3.8

  17 beta-HSD1 is a novel target for the treatment of estrogen-dependent diseases, as it catalyzes intracellular estradiol formation. Starting from two recently described compounds, highly active and selective inhibitors were developed. Benzoyl 6 and benzamide 17 are the most selective compounds toward 17 beta-HSD2 described so far. They also showed a promising profile regarding activity in T47-D cells, selectivity toward ER alpha and ER beta inhibition of hepatic CYP enzymes, metabolic stability, and inhibition of marmoset 17 beta-HSD1 and 17 beta-HSD2.